{"id":87934,"date":"2019-02-18T23:03:23","date_gmt":"2019-02-19T07:03:23","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/02\/investors-bet-billions-on-health-care-start-ups-with-paltry-publication-records"},"modified":"2019-02-18T23:03:23","modified_gmt":"2019-02-19T07:03:23","slug":"investors-bet-billions-on-health-care-start-ups-with-paltry-publication-records","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/02\/investors-bet-billions-on-health-care-start-ups-with-paltry-publication-records","title":{"rendered":"Investors bet billions on health-care start-ups with paltry publication records"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/investors-bet-billions-on-health-care-start-ups-with-paltry-publication-records2.jpg\"><\/a><\/p>\n<p>I remember the #DotCom crash all too well.<\/p>\n<p>The publication record of health-care start-up companies doesn\u2019t seem to matter to investors, according to an analysis of nearly 50 biomedical \u2018unicorns\u2019 \u2014 venture-capital-backed companies valued at more than US$1 billion. The analysis, led by health-policy researcher John Ioannidis at Stanford University in California, finds no correlation between a company\u2019s market valuation and its publication record \u2014 defined as the number of peer-reviewed papers authored directly by a firm. That\u2019s a cause for concern, the authors say.<\/p>\n<hr>\n<p>Firms can achieve f\u00eated \u2018unicorn\u2019 valuations without publishing much peer-reviewed science. Health-care start-ups can reach billion-dollar valuations without publishing in peer-reviewed journals, but skipping that step can catch them out.<\/p>\n<p><!-- Link: <a href=\"https:\/\/www.nature.com\/articles\/d41586-019-00564-5\">https:\/\/www.nature.com\/articles\/d41586&#45;019&#45;00564&#45;5<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>I remember the #DotCom crash all too well. The publication record of health-care start-up companies doesn\u2019t seem to matter to investors, according to an analysis of nearly 50 biomedical \u2018unicorns\u2019 \u2014 venture-capital-backed companies valued at more than US$1 billion. The analysis, led by health-policy researcher John Ioannidis at Stanford University in California, finds no correlation [\u2026]<\/p>\n","protected":false},"author":507,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495,31],"tags":[],"class_list":["post-87934","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health","category-policy"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/87934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/507"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=87934"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/87934\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=87934"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=87934"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=87934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}